期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

艾塞那肽治疗2型糖尿病的临床观察 被引量：4

在线阅读 下载PDF
导出
摘要 近年来随着对2型糖尿病研究的深入,发现人胰高血糖素样肽-1(GLP-1)不仅能促进胰岛素释放,还有改善糖尿病相关的胰岛β细胞功能缺陷的作用[1]。目前GLP-1类似物已运用于临床治疗2型糖尿病患者。我科2009年首次将GLP-1类似物艾塞那肽用于治疗2型糖尿病患者。
作者 倪洪岗 李雪梅
机构地区 贵阳中医学院第二附属医院内分泌科
出处 《贵州医药》 CAS 2011年第3期245-247,共3页 Guizhou Medical Journal
关键词 塞那 胰岛Β细胞功能 胰岛素释放 临床观察 类似物 人胰高血糖素 口服降糖药 Β细胞 低血糖事件 胰高血糖素分泌
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献10

  • 1Nielsen LL,Young AA,Parkes DG.Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides . 2004
  • 2Szayna M,Doyle ME,Betkey JA,et al.Exendin-4 decelerates food intake, weight gain and fat deposition in Zucker rats. The Journal of Endocrinology . 2000
  • 3Egan JM,,Clocqet AR,Elahi D.The insulinotropic effectof acute exendin-4 administrered to humans:compari-son of nondiabetic state to type 2 diabetes. J C1inEndocrinol Metab . 2002
  • 4Parkes DG,Pittner R,Jodka C,et al.Insulinotropic ac-tions of exendin-4 and glucagon-like peptide-l in vivoand in vitro. Metabolism . 2001
  • 5Gedulin,BR,Nikoulina,SE,Smith,PA.Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. The Journal of Endocrinology . 2005
  • 6Rayner CK,Samsom M,Jones KL, et al.Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care . 2001
  • 7刘惠侠,曾璐琳.新型降糖药exenatide的研究进展[J].世界临床药物,2005,26(11):691-694. 被引量：8
  • 8王育璠,彭永德.胰高血糖素样肽-1——2型糖尿病治疗的新策略[J].世界临床药物,2004,25(12):718-721. 被引量：4
  • 9Egan JM,Bulotta A,Hui H,et al.GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metabolism Reviews . 2003
  • 10刘彦君.从三重唱到八重奏——2型糖尿病治疗的新模式 第68届美国糖尿病学术年会Banting奖介绍[J].中华医学信息导报,2008,23(17):18-19. 被引量：4

二级参考文献10

  • 1Stoffers DA,Desai BM,Deleon DD,et al.Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat[].Diabetes.2003
  • 2Pederson RA,White HA,Schlenzig D,et al.Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide[].Diabetes.1998
  • 3Kieffer TJ.Gastro-inlestinal hormones GIP and GLP-1[].Annales d Endocrinologie.2004
  • 4Nielsen LL,Young AA,Parkes DG.Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes[].Regulatory Peptides.2004
  • 5Kolterman OG,Buse JB,Fineman MS,et al.Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes[].The Journal of Clinical Endocrinology.2003
  • 6Tourrel C,Bailbe D,Meile MJ,et al.Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age[].Diabetes.2001
  • 7Hoist JJ.Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential[].Trends in Endocrinology and Metabolism.1999
  • 8Juhl CB,Hollingdal M,Sturis J,et al.Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes[].Diabetes.2002
  • 9Fineman MS,Shen LZ,Taylor K,et al.Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes[].Diabetes Metabolism Reviews.2004
  • 10Egan JM,Meneilly GS,Elahi D.Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes[].American Journal of Physiology Endocrinology and Metabolism.2003

共引文献11

同被引文献19

  • 1刘惠侠,曾璐琳.新型降糖药exenatide的研究进展[J].世界临床药物,2005,26(11):691-694. 被引量：8
  • 2Kones R. Primary prevention of coronary heart disease: inte- gration of new data, evolving view, revised goal, and role of rosuvasta- tion in management A comprehensive survey. DrugDes Devel Ther 2011 ;5:325 - 380.
  • 3Nathan DM. Finding new treatments for diabetes - how many, how fast? How good N Engl J Med 2007 ;5:437 -440.
  • 4Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011 ;1:40 -51.
  • 5Horton ES, Silberman C , Davis KL, et al. Weight loss, gly- cemic control, and changes in candiovascular biomarkers in patients with type 2 diabetes receiting incretin therapies or insulin in a large co- bort database. Diabetes Care 2010;33:1759 - 1765.
  • 6Glass LC , Qu Y , Lenox S , et al. Effects of exenatide versus insulin analagues on weight change in subjects with type 2 diabetes a pooled post - hoc analysis. Curr Med Res Opin 2008 ; 24 : 639 - 6344.
  • 7G. Parnaud,D. Bosco,T. Berney,F. Pattou,J. Kerr-Conte,M. Y. Donath,C. Bruun,T. Mandrup-Poulsen,N. Billestrup,P. A. Halban.Proliferation of sorted human and rat beta cells[J].Diabetologia.2008(1)
  • 8M. A. Nauck,S. Duran,D. Kim,D. Johns,J. Northrup,A. Festa,R. Brodows,M. Trautmann.A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study[J].Diabetologia.2007(2)
  • 9Nielsen LL,Young AA,Parkes DG.Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes[].Regulatory Peptides.2004
  • 10Kendall DM,Riddle MC,Rosenstock J,et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[].Diabetes Care.2005

引证文献4

二级引证文献7

贵州医药
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部